SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Covalent Group Inc (CVGR) an undiscovered CRO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ForYourEyesOnly who wrote (51)4/20/1998 12:18:00 PM
From: Gurupup  Read Replies (1) of 107
 
When a stock is down and out, it is nice to see insider buying.

CVGR recruited Kenneth M. Borow, M.D., a senior executive from Merck
& Co., to serve as the company's Chief Medical Officer, and to assume responsibility for all
contract research activities. A Harvard-trained physician who conducted and managed clinical
research while a Professor of Medicine at the University of Chicago, Dr. Borow spent the past four
years conducting and overseeing clinical research programs at Merck.

(Dr. Borow bought 5,000 shares of CVGR on 4/14/98 at $2.19 bringing holdings to 34,200, as reported by the SEC.)

This to me is a very healthy sign for the future.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News